Lazapir

Olanzapine, the active ingredient in Lazapir, is an atypical antipsychotic presented as an oral formulation for oral use. It is indicated for the treatment of schizophrenia and bipolar disorder in adults.

GNH USA supplies Lazapir as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olanzapine is an atypical antipsychotic that modulates dopamine and serotonin pathways in major psychiatric disorders. - Schizophrenia: reduces psychotic symptoms and relapse risk. - Bipolar disorder (manic episodes): controls elevated mood, agitation and impulsivity. - Bipolar disorder (maintenance): helps maintain mood stability and prevent recurrence. - Schizoaffective disorder: treats both psychotic and mood components.

Olanzapine may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Weight gain: increased appetite leading to noticeable weight increase. - Sedation: drowsiness or feeling unusually sleepy. - Dry mouth: reduced salivation causing oral discomfort. - Constipation: slowed gastrointestinal motility. - Increased appetite: heightened desire for food. - Dizziness: light‑headedness, especially when standing quickly.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: life‑threatening reaction with fever and muscle rigidity. - Agranulocytosis: severe drop in white blood cells increasing infection risk. - Hyperglycemia: marked increase in blood sugar levels, may precipitate diabetes. - Tardive dyskinesia: involuntary movements of facial muscles and tongue. - Seizures: occurrence of convulsive episodes. - Myocarditis: inflammation of heart muscle, rare but serious.

When prescribing Olanzapine, clinicians should consider several safety precautions. - Pregnancy: limited data; use only if potential benefit justifies risk. - Breastfeeding: assess risk; drug may pass into milk. - Metabolic monitoring: regularly check weight, glucose and lipid levels. - Elderly patients: increased sensitivity to sedation and fall risk. - Driving and operating machinery: may cause drowsiness; advise caution. - Store at room temperature: keep in original container, protect from moisture and light.

Olanzapine can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - CYP1A2 inhibitors (e.g., fluvoxamine): may raise olanzapine plasma concentrations. - CYP1A2 inducers (e.g., smoking, carbamazepine): may lower olanzapine levels. - CNS depressants (e.g., benzodiazepines, alcohol): can cause excessive sedation.

Moderate Interactions (Monitor Closely): - Antidiabetic agents: olanzapine may impair glucose control. - Antihypertensives: additive hypotensive effect possible. - Lithium: monitor for signs of neurotoxicity. - Anticholinergic drugs: may increase anticholinergic burden. - Antihistamines: may enhance sedation.